Noticias de TEM_US

Mercado

Noticias del mercado

Últimas noticias sobre TEM_US — 640 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: TEM_US ✕ 640 resultados
20/07/2026 TEM_US — GuruFocus
Tempus AI (TEM) to Acquire Personalis in Strategic Move
20/07/2026 TEM_US — Investing.com ES ← LA
Es hora de adquirir Personal por 1.500 millones de dólares

Tempus to acquire Personalis for $1.5 billion

20/07/2026 TEM_US — GuruFocus
Tempus AI Inc to Acquire Personalis Inc Transcript
20/07/2026 TEM_US — Investing.com ES ← LA
Es hora de adquirir Personal por 1.500 millones de dólares Por Investing.com

Tempus to acquire Personalis for $1.5 billion By Investing.com

20/07/2026 TEM_US — Moomoo
Tempus AI Inc - Maximum Exchange Ratio Set at
20/07/2026 TEM_US — Moomoo
Tempus AI Inc - Cash Consideration Will Be Fi
20/07/2026 TEM_US — MLex
US health tech firm Tempus AI plans to acquire cancer diagnostics firm Personalis
20/07/2026 TEM_US — Moomoo
Press Release: Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) Into Its AI-Enabled Precision Oncology Platform
20/07/2026 TEM_US — DirectorsTalk Interviews
Tempus AI, Inc. (TEM) Stock Analysis: Navigating a 27.81% Potential Upside in Health Information Services
20/07/2026 TEM_US — Business Wire
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
20/07/2026 TEM_US — Modern Healthcare
Tempus AI to buy cancer-tech firm Personalis for $1.7B

Se espera que el acuerdo se cierre a finales de 2026 o principios de 2027.

20/07/2026 TEM_US — Stock Titan
Tempus AI (NASDAQ: TEM) plans $1.5B all-stock acquisition of Personalis
20/07/2026 TEM_US — Yahoo Finance
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
20/07/2026 TEM_US — The Business Journals
Tempus AI to acquire Personalis for $1.5B
20/07/2026 TEM_US — Stock Titan
Tempus AI (NASDAQ: TEM) to buy Personalis in $1.5B cancer MRD deal
20/07/2026 TEM_US — Investing.com
Needham reiterates Tempus AI stock rating after Personalis deal
20/07/2026 TEM_US — HIT Consultant
M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring
20/07/2026 TEM_US — Benzinga
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition

Las acciones de Tempus AI caen después de que un acuerdo de Personalis por valor de 1.500 millones de dólares amplíe su alcance en el mercado de MRD de 20.000 millones de dólares.

20/07/2026 TEM_US — finance.biggo.com
Tempus AI Plunges as Investors Question $1.5 Billion Cash Buyout of Personalis

Las acciones de Tempus AI cayeron un 8,8% a 47,81 dólares después de que la compañía anunciara una adquisición en efectivo por 1.500 millones de dólares de la empresa de diagnóstico del cáncer Personalis en...

20/07/2026 TEM_US — Reuters
Tempus to buy cancer test maker Personalis for $1.5 billion

Página 16 de 32